Nanovibronix (FEED) Competitors

$1.01 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.00 (+0.20%)

As of 05/22/2026 07:59 PM Eastern

FEED vs. IINN, MBAI, SURG, ALUR, and QNRX

Should you buy Nanovibronix stock or one of its competitors? MarketBeat compares Nanovibronix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nanovibronix include Inspira Technologies OXY B.H.N. (IINN), Check-Cap (MBAI), SurgePays (SURG), Allurion Technologies (ALUR), and Quoin Pharmaceuticals (QNRX). These companies are all part of the "medical equipment" industry.

How does Nanovibronix compare to Inspira Technologies OXY B.H.N.?

Nanovibronix (NASDAQ:FEED) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Inspira Technologies OXY B.H.N. has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-923.20%	-54.25%	-43.10%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

Nanovibronix has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market.

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 1.4% of Nanovibronix shares are held by company insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Nanovibronix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	2.41	-$18.18M	-$41.74	N/A
Inspira Technologies OXY B.H.N.	$289K	90.43	-$13.22M	N/A	N/A

In the previous week, Inspira Technologies OXY B.H.N. had 2 more articles in the media than Nanovibronix. MarketBeat recorded 3 mentions for Inspira Technologies OXY B.H.N. and 1 mentions for Nanovibronix. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.40 beat Nanovibronix's score of 0.00 indicating that Inspira Technologies OXY B.H.N. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inspira Technologies OXY B.H.N. has a consensus target price of $2.00, indicating a potential upside of 175.10%. Given Inspira Technologies OXY B.H.N.'s stronger consensus rating and higher possible upside, analysts plainly believe Inspira Technologies OXY B.H.N. is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Inspira Technologies OXY B.H.N. beats Nanovibronix on 12 of the 14 factors compared between the two stocks.

How does Nanovibronix compare to Check-Cap?

Check-Cap (NASDAQ:MBAI) and Nanovibronix (NASDAQ:FEED) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Check-Cap and Check-Cap both had 1 articles in the media. Check-Cap's average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Check-Cap has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by company insiders. Comparatively, 1.4% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Check-Cap has higher earnings, but lower revenue than Nanovibronix. Check-Cap is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Nanovibronix	$2.55M	2.41	-$18.18M	-$41.74	N/A

Check-Cap has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Check-Cap's return on equity of 0.00% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Nanovibronix	-923.20%	-54.25%	-43.10%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Check-Cap and Nanovibronix tied by winning 5 of the 10 factors compared between the two stocks.

How does Nanovibronix compare to SurgePays?

SurgePays (NASDAQ:SURG) and Nanovibronix (NASDAQ:FEED) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

SurgePays has a net margin of -64.91% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
Nanovibronix	-923.20%	-54.25%	-43.10%

SurgePays has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 29.1% of SurgePays shares are owned by insiders. Comparatively, 1.4% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nanovibronix has lower revenue, but higher earnings than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.22	-$36.07M	-$1.94	N/A
Nanovibronix	$2.55M	2.41	-$18.18M	-$41.74	N/A

SurgePays presently has a consensus target price of $5.00, indicating a potential upside of 896.02%. Given SurgePays' stronger consensus rating and higher possible upside, equities research analysts clearly believe SurgePays is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Nanovibronix had 1 more articles in the media than SurgePays. MarketBeat recorded 1 mentions for Nanovibronix and 0 mentions for SurgePays. SurgePays' average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.

Company	Overall Sentiment
SurgePays	Neutral
Nanovibronix	Neutral

Summary

Nanovibronix beats SurgePays on 8 of the 15 factors compared between the two stocks.

How does Nanovibronix compare to Allurion Technologies?

Allurion Technologies (NYSE:ALUR) and Nanovibronix (NASDAQ:FEED) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, Nanovibronix had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 1 mentions for Nanovibronix and 0 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.

Company	Overall Sentiment
Allurion Technologies	Neutral
Nanovibronix	Neutral

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 8.1% of Allurion Technologies shares are owned by insiders. Comparatively, 1.4% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Allurion Technologies currently has a consensus price target of $3.00, suggesting a potential upside of 261.71%. Given Allurion Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Allurion Technologies is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Allurion Technologies has a net margin of -199.96% compared to Nanovibronix's net margin of -923.20%. Allurion Technologies' return on equity of 0.00% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Nanovibronix	-923.20%	-54.25%	-43.10%

Allurion Technologies has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Allurion Technologies has higher revenue and earnings than Nanovibronix. Allurion Technologies is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.72	-$7.20M	-$10.56	N/A
Nanovibronix	$2.55M	2.41	-$18.18M	-$41.74	N/A

Summary

Allurion Technologies beats Nanovibronix on 10 of the 15 factors compared between the two stocks.

How does Nanovibronix compare to Quoin Pharmaceuticals?

Nanovibronix (NASDAQ:FEED) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 1.4% of Nanovibronix shares are owned by insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-923.20%	-54.25%	-43.10%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Quoin Pharmaceuticals has lower revenue, but higher earnings than Nanovibronix. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	2.41	-$18.18M	-$41.74	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

In the previous week, Nanovibronix and Nanovibronix both had 1 articles in the media. Nanovibronix's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanovibronix has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nanovibronix and Quoin Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get Nanovibronix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEED vs. The Competition

Export

Metric	Nanovibronix	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$6.15M	$3.22B	$4.26B	$12.34B
Dividend Yield	N/A	N/A	5.93%	5.28%
P/E Ratio	-0.02	2.51	21.90	25.66
Price / Sales	2.41	455.93	180.63	86.31
Price / Cash	N/A	3.94	55.68	56.67
Price / Book	0.19	3.20	34.85	7.14
Net Income	-$18.18M	-$76.79M	$112.32M	$335.98M
7 Day Performance	8.60%	1.67%	3.54%	4.15%
1 Month Performance	-24.63%	-2.02%	3.59%	2.54%
1 Year Performance	N/A	100.00%	15.80%	35.06%

Nanovibronix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEED Nanovibronix	1.0691 of 5 stars	$1.01 flat	N/A	N/A	$6.15M	$2.55M	N/A	20	Gap Down
IINN Inspira Technologies OXY B.H.N.	1.9719 of 5 stars	$0.39 +2.4%	$2.00 +414.1%	+53.1%	$13.66M	$289K	N/A	20	Gap Up High Trading Volume
MBAI Check-Cap	0.2661 of 5 stars	$1.83 +1.1%	N/A	N/A	$13.19M	N/A	N/A	80
SURG SurgePays	2.1844 of 5 stars	$0.50 -4.8%	$5.00 +899.8%	-83.6%	$13.19M	$56.96M	N/A	40	Earnings Report Gap Up
ALUR Allurion Technologies	N/A	$0.85 -6.5%	$3.00 +252.5%	-70.1%	$12.76M	$17.21M	N/A	501	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEED) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanovibronix (FEED) Competitors

FEED vs. IINN, MBAI, SURG, ALUR, and QNRX

How does Nanovibronix compare to Inspira Technologies OXY B.H.N.?

Summary

How does Nanovibronix compare to Check-Cap?

Summary

How does Nanovibronix compare to SurgePays?

Summary

How does Nanovibronix compare to Allurion Technologies?

Summary

How does Nanovibronix compare to Quoin Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanovibronix (FEED) Competitors

FEED vs. IINN, MBAI, SURG, ALUR, and QNRX

How does Nanovibronix compare to Inspira Technologies OXY B.H.N.?

Is FEED or IINN more profitable?

Which has more risk & volatility, FEED or IINN?

Do insiders & institutionals believe in FEED or IINN?

Which has higher earnings & valuation, FEED or IINN?

Does the media prefer FEED or IINN?

Do analysts rate FEED or IINN?

Summary

How does Nanovibronix compare to Check-Cap?

Does the media favor MBAI or FEED?

Which has more volatility and risk, MBAI or FEED?

Do institutionals and insiders have more ownership in MBAI or FEED?

Which has stronger valuation and earnings, MBAI or FEED?

Is MBAI or FEED more profitable?

Do analysts prefer MBAI or FEED?

Summary

How does Nanovibronix compare to SurgePays?

Is SURG or FEED more profitable?

Which has more risk & volatility, SURG or FEED?

Do institutionals & insiders have more ownership in SURG or FEED?

Which has better earnings & valuation, SURG or FEED?

Do analysts prefer SURG or FEED?

Does the media favor SURG or FEED?

Summary

How does Nanovibronix compare to Allurion Technologies?

Does the media prefer ALUR or FEED?

Do insiders & institutionals hold more shares of ALUR or FEED?

Do analysts recommend ALUR or FEED?

Is ALUR or FEED more profitable?

Which has more volatility and risk, ALUR or FEED?

Which has better earnings & valuation, ALUR or FEED?

Summary

How does Nanovibronix compare to Quoin Pharmaceuticals?

Do institutionals and insiders believe in FEED or QNRX?

Is FEED or QNRX more profitable?

Which has stronger earnings and valuation, FEED or QNRX?

Does the media refer more to FEED or QNRX?

Which has more risk & volatility, FEED or QNRX?

Do analysts recommend FEED or QNRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools